Compare XBIO & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIO | CPHI |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.8M |
| IPO Year | N/A | N/A |
| Metric | XBIO | CPHI |
|---|---|---|
| Price | $2.08 | $1.29 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.9K | ★ 53.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,858,935.00 | ★ $4,052,266.00 |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $1.90 | $1.18 |
| 52 Week High | $13.93 | $3.35 |
| Indicator | XBIO | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 33.45 |
| Support Level | $1.90 | $1.30 |
| Resistance Level | $2.29 | $1.49 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 25.68 | 17.14 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.